Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 7/20 | 0.44 |
| ▸ | PPIA | P62937 | 1/20 | 0.44 |
| ▸ | PGK1 | P00558 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721556 | 1.00 | TSHR (0.50) | TSHRMAPK1CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL1626324 | 0.91 | TSHR (0.50) | TSHRMAPK1CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL772624 | 0.89 | CYP1A2 (0.48) | TSHRMAPK1CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL3633645 | 0.89 | TSHR (0.52) | TSHRMAPK1CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL31592017 | 0.89 | TSHR (0.52) | TSHRMAPK1CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL29586844 | 0.87 | PPIA (0.47) | TSHRMAPK1CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL80032 | 0.87 | PPIA (0.47) | TSHRMAPK1CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL16013560 | 0.87 | TSHR (0.50) | TSHRMAPK1CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL359519 | 0.84 | TSHR (0.60) | TSHRMAPK1CYP3A4ALDH1A1VCAM1 | |
| SCHEMBL5068830 | 0.83 | PPIA (0.47) | TSHRMAPK1CYP3A4ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114656407-B | Method for preparing saflufenacil intermediate | 帕潘纳(北京)科技有限公司 | 2023-06-16 | — | — | CN | claimed |
| CN-112851493-B | Preparation method of 2,4, 5-trifluoro phenylacetic acid | 台州臻挚生物科技有限公司 | 2022-09-06 | — | — | CN | claimed |
| CN-114656407-A | Method for preparing saflufenacil intermediate | 帕潘纳(北京)科技有限公司 | 2022-06-24 | — | — | CN | claimed |
| WO-2022099439-A1 | PREPARATION METHOD FOR 2,4,5-TRIFLUOROPHENYLACETIC ACID | 杭州臻挚生物科技有限公司 | 2022-05-19 | — | — | WO | claimed |
| CN-112851493-A | Preparation method of 2,4, 5-trifluorophenylacetic acid | 杭州臻挚生物科技有限公司 | 2021-05-28 | — | — | CN | claimed |
| US-5808164-A | Process for producing aromatic sulfides | PHILLIPE PETROLEUM COMPANY (US) | 1998-09-15 | — | — | US | claimed |
| US-5618981-A | Process for producing aromatic sulfides | PHILLIPS PETROLEUM COMPANY (US) | 1997-04-08 | — | — | US | claimed |
| CN-118271267-A | Compound for organic electroluminescent device, application of compound and organic electroluminescent device | 北京鼎材科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-114656407-B | Method for preparing saflufenacil intermediate | 帕潘纳(北京)科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-112851493-B | Preparation method of 2,4, 5-trifluoro phenylacetic acid | 台州臻挚生物科技有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-114656407-A | Method for preparing saflufenacil intermediate | 帕潘纳(北京)科技有限公司 | 2022-06-24 | — | — | CN | disclosed |
| WO-2022099439-A1 | PREPARATION METHOD FOR 2,4,5-TRIFLUOROPHENYLACETIC ACID | 杭州臻挚生物科技有限公司 | 2022-05-19 | — | — | WO | disclosed |
| CN-112851493-A | Preparation method of 2,4, 5-trifluorophenylacetic acid | 杭州臻挚生物科技有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| EP-1960389-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007036718-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| US-5808164-A | Process for producing aromatic sulfides | PHILLIPE PETROLEUM COMPANY (US) | 1998-09-15 | — | — | US | disclosed |
| US-5618981-A | Process for producing aromatic sulfides | PHILLIPS PETROLEUM COMPANY (US) | 1997-04-08 | — | — | US | disclosed |
| US-4846875-A | PLANT GROWTH REGULATORS | FMC CORPORATION (US) | 1989-07-11 | — | — | US | disclosed |
| US-4102924-A | REACTING ACYLAMINO-ARYLS WITH HALO-ARYLS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293770-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses In Medicine | CHRM1, CHRM2, CHRM5 | TSHR 53/4885MAPK1 936/4885CYP3A4 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.